STORY DEVELOPMENT
What’s your Story?
Co-creating the stories that add value and meaning to your business, brand and culture.
Roche Bispecifics:
Patient tailored solutions
Stakeholder Insights
Clinical Strategy
Portfolio Strategy
Animation
Identity
Portfolio Storytelling
Stakeholder Insights / Clinical Strategy / Portfolio Strategy / Animation / Identity
Roche is pioneering the development of T-cell engaging bispecific antibodies with potential across multiple blood cancers, including Non-Hodgkin’s lymphoma (NHL).
A key challenge was that it had two bispecifics – (mosunetuzumab and glofitamab) launching at similar times. To resolve the potential for confusion, our story “Patient tailored solutions” emphasized the need for a diversity of solutions in the face of heterogenous b-cell lymphomas.
Bexsero:
It could be you
Brand Strategy / Story Journals / Story Development / Positioning
Brand Storytelling
Brand Strategy
Story Journals
Story Development
Positioning
Bexsero is a vaccine for Meningitis B – a rare infection that can kill within days if untreated.
It wasn’t thought to be endemic to the US until outbreaks at two colleges on opposite sides of the country prompted authorities to request an expedited approval of the vaccine.
We uncovered that when the disease was seen as “rare” by students and physicians, there was little urgency to act; but when we reframed it as “random,” they were far more motivated to vaccinate. With the resulting story, “It could be you,” Bexsero was well placed at launch to extend protection to at-risk students.
AAA:
Imagine what more we can do
Advanced Accelerator Applications (AAA) is a leader in the rapidly emerging field of radioligand therapy (RLT).
Following its purchase by Novartis, the US AAA leadership team asked Make Believe to craft a story to help employees embrace the change.
“Imagine what more we can do” celebrated AAA’s success in developing RLT and invited employees to consider how much further they could go with the backing of Novartis. The company is now the leading provider of RLT worldwide.
Culture Strategy
Stakeholder Insight
Cultural Story
Identity
Change Management
Culture Strategy / Stakeholder Insight /
Cultural Story / Identity / Change Management
Cultural Storytelling
Ocrevus:
Completing the picture in MS
Brand Strategy
Stakeholder Insights
Clinical Story
Brand Strategy / Stakeholder Insights / Clinical Story
Science Story
Ocrevus (ocrelizumab) was widely adopted by the Multiple Sclerosis medical community at launch. However, it was primarily being used as a switch therapy, limiting its potential for patients.
To prompt first-line use, Roche needed to shift the MS medical community from focus on symptoms to progression as a key aim of therapy that Ocrevus could uniquely meet. “Completing the picture in MS” led to a reappraisal of MS treatment goals and earlier consideration of the drug.
ALK Reweal:
ALK Reweal: Best in both worlds
Portfolio Storytelling
Stakeholder Insights
Access Strategy
Access Story
Website
Animation
ALK is the world's leading maker of immunotherapies for people with allergies. It launched an extensive real-world evidence program to show the long-term value of allergy immunotherapy.
It sought a story to bridge its clinical trial and real-world evidence programs to share with payors. “Best in both worlds” helped show the breadth and depth of evidence behind its products, confirming its commitment to the field, leading to favorable access decisions in several markets.
